Abstract: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.

Abstract: One aspect of the present application relates to a covering member for a protruding portion of a patient's body. This cover is flexible and collapsible so that it conforms to the shape of the encased portion of the body.

Abstract: Medical patch device mountable on skin for drug delivery or analyte sensing, including a mounting base (6) comprising a support layer (12) and an adhesive layer (14) on a mounting side (36) of the support layer, and a functional unit (4) comprising a power supply, and an electronic circuit. The adhesive layer comprises a light switchable adhesive and the support layer is formed as a light guide configured to diffuse light from one or more electronically activated light sources connected to the electronic circuit of the functional unit.

Abstract: A skin patch for absorbing toxins from a body includes a first side having a heat reflective foil. A second side includes a non-woven rayon surface for absorbing the toxins. The rayon surface includes a plurality of openings for enhancing far infrared ray emission into a skin when the second side is placed in contact with the skin. A mixture of natural ingredients includes vinegar, chitosan, loquat leaf, houttuynia cordata, vitamin C, tourmaline, vegetable fiber, and dextrin. The mixture is formulated to emit the far infrared emission, whereby blood circulation is promoted and perspiration and any toxins contained therein are absorbed by the rayon surface.

Abstract: An aqueous solution of polyacrylic acid is placed in a mold, frozen, and freeze-dried to form a sponge-like polyacrylic acid structure. The sponge-like polyacrylic acid structure is compressed by the application of heat and pressure to reduce the thickness and increase the density of the sponge-like polyacrylic acid structure to form a densified polyacrylic acid structure. The densified polyacrylic acid structure is preconditioned by heating to form a wound dressing. The wound dressing can be applied to control severe, life-threatening bleeding from a wound at a wound site of a person.

Abstract: An apparatus for fluid collection is disclosed, which comprises: a frame, composed of a plurality of unit cells, each being made of an absorbent polymer composite; and a bag, for receiving the frame while being connected to a conduit provided for enabling a fluid to flow in and out the bag therethrough.

Abstract: An external patch containing diclofenac hydroxyethylpyrrolidine prepared by laminating an adhesive layer on a backing, wherein said adhesive layer is characterized by comprising 5-50% by weight of styrene•isoprene•styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent, and 0.5-20% by weight of one or more solubilizers selected from N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide as essential ingredients, and 0.5-20% by weight of diclofenac hydroxyethylpyrrolidine as an active ingredient. The patch has excellent transdermal absorption, less skin-irritation and excellent stability of the drug.

Abstract: The present invention comprises antimicrobial articles for use with a percutaneous device, comprising a matrix which may contact the percutaneous device in a three-dimensional mode and release antimicrobial agents (e.g., silver ions) to the percutaneous device access site. In addition, the antimicrobial article of the present invention may donate moisture to a dry dermal site (e.g., a dry wound bed) and/or absorb liquid or exudates of a dermal site. The present invention also comprises methods for treating and/or preventing an infection using the antimicrobial articles of the present invention.

Abstract: A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch.

Abstract: The invention relates to a transdermal therapeutic system made of the following layers: a carrier layer (T), an active ingredient layer (R), a membrane layer (M) and optionally an adhesive layer (K), wherein the carrier layer (T) is impenetrable to the active substance and to water, the active substance layer (R) comprises as an active substance component the salt of an alkali reactive active substance, such as a CNS-active amine in combination with at least one alkali reactive further component, and a polymer component (P1), wherein the active substance is released from the active substance layer (R) only by the moisture entering from the exterior through the membrane layer (M), and the membrane layer (M) is made of a polymer component (P2), allowing a uniform delivery of basic active substances to the skin.

Abstract: The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.

Abstract: A transdermal drug delivery patch has an excipient matrix containing an agonist for administration across the skin of a user, with the matrix further containing a plurality of spaced apart hollow cilia filled with an antagonist, whereby if an abuser attempts to physically remove the agonist the cilia will break releasing the antagonist, or if the abuser attempts In use a solvent to remove the agonist the cilia will dissolve releasing the antagonist, thereby blocking the effect the abuser is attempting to attain by concentrating the agonist for oral ingestion or by hypodermic needle injection. The plurality of spaced apart hollow cilia further includes a release enhancing agent in association with the antagonist for increasing the release rate of the antagonist.

Abstract: This invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 days.

Abstract: Disclosed is a transdermally absorbable preparation, in which an adhesive agent produced by crosslinking at least one copolymer is contained in an adhesive layer and the aging period in the production of the adhesive layer can be shortened. The transdermally absorbable preparation comprises a support and an adhesive layer arranged on the support and containing an adhesive agent and a medicinal component. The transdermally absorbable preparation is characterized in that the adhesive agent comprises a resin mixture comprising 100 parts by mass of a specific acrylic copolymer (A) and 0.1 to 30 parts by mass of a specific acrylic copolymer (B) or 0.05 to 2 part(s) by mass of a polyamine compound, and the adhesive layer additionally contains an organic acid.

Abstract: The present invention relates to compositions including a homeopathic aqueous substance active (HASA) and at least one hydrophilic gelling agent, the HASA comprises a homeopathic compound at a potency of 30 C or higher and an uninhibited aqueous composition. The present invention also relates to methods of preparing a hydrophilic HASA-gel matrix. The method includes combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; combining the HASA with at least one hydrophilic gelling agent; and thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.

Abstract: Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the organic base. Compositions and transdermal systems are also described.

Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.

Abstract: A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Abstract: Disclosed is a transdermal therapeutic system for administering an active ingredient through the skin comprising: a) a back layer, b) a reservoir on the back layer comprising b1) a first layer containing active ingredient, at least one gel former, at least one plasticizer, and a first polyisobutylene; and b2) a second layer containing active ingredient, at least one gel former, at least one plasticizer, and a second polyisobutylene, wherein the first polyisobutylene is different from the second polyisobutylene, wherein at least the first layer contains undissolved active ingredient in the form of active ingredient particles; and wherein the active ingredient is fentanyl or an analogue of the fentanyl.

Abstract: A suction head in fluid communication with a pump head provides a sub-ambient working pressure to a target area, enabling drainage thereof to a waste container. The pump head is coupled non-mechanically to a pump drive. A control system for a suction system is also provided.

Abstract: Disclosed is a pharmaceutical composition containing rivastigmine. Specifically, disclosed is a transepidermal drug delivery system including a rivastigmine-containing drug layer and a supporter adhered to one surface of the drug layer to support the drug layer, wherein the drug layer contains 10 to 40 parts by weight of a rubber, 20 to 80 parts by weight of a rosin ester resin and 0.1 to 10 parts by weight of an acrylic adhesive and the drug layer has a thickness of 40 ?m to 100 ?m.

Abstract: An architecture is presented that provides a topical cream delivery device designed for effectively and easily administering hydrating and pain-relieving creams to dialysis patients' and other “in need” patients' needle sites. The topical cream delivery device comprises an adhesive bandage strip and a cavity positioned along the adhesive bandage strip. The cavity is typically filled with a hydrating and pain-relieving cream for dialysis patients, but could be filled with any other suitable cream or drug as well. The adhesive bandage strip further comprises an adhesive backing, for adhering to a user's skin. The adhesive bandage strip is attached to the adhesive backing on one side and covered with a protective paper on the other and cut to shape for application to a body surface. A user when using the topical cream delivery device peels off the protective paper from the adhesive backing and adheres the device to a body surface.

Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Abstract: An apparatus configured to provide a beneficial biological effect for a subject, and/or a method of treating the subject using the apparatus. The apparatus may be configured to trigger and maintain the elevation of Glutathione levels within the subject. The apparatus may rely on a non-invasive mechanism to elevate Glutathione levels in the subject. The apparatus may not require a traditional power source such as a battery or wall plug in order to be effective in elevating Glutathione levels in the subject. To trigger and maintain the elevation of Glutathione levels within the subject, the apparatus may transmit communication to the body of the subject that results in increased levels of Glutathione within the subject.

Abstract: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Abstract: A reduced-pressure, linear-wound closing bolster has a pivotable frame that moves from an extended position to a compressed position under the influence of reduced pressure. The closing bolster may have a first closing member, a second closing member, and an interior space. A manifold member is disposed within the interior space and may be coupled to the pivotable frame. When a reduced pressure is applied, the pivotable frame is urged from the extended position to the compressed position. A first gripping member for transmitting a closing force from the first closing member to a first edge of a linear wound may be attached. Likewise, a second gripping member for transmitting a closing force from the second closing member to a second edge of the linear wound may be attached. Systems and methods are also presented.

Abstract: The present invention relates to a skin patch comprising a matrix adhering to the skin and containing at least one active cosmetic substance and a combination with a skin wrapping to generate an effective compression for the treatment of cellulite and/or striae.

Abstract: An antiviral transdermal patch including a backing layer, a viscous polymer layer, and a protection film layer. The viscous polymer layer includes an antiviral agent, a viscous polymer, and a transdermal enhancer. The transdermal enhancer is laurocapram or a mixture thereof. The antiviral agent is a nucleoside antiviral drug with a daily delivery rate of less than 100 mg/day. The patch effectively promotes the penetration of a nucleoside antiviral agent into the blood circulation and avoids enzymolysis in the gastrointestinal tract and the first pass effect of the liver and reduces side effect of drugs, thereby inhibiting the replication of target viruses and reducing viral DNA level in the serum. A method for producing the patch is also provided. The raw materials involved in the invention are easily purchased from the market at a low cost.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: A system for treating a linear wound on a patient has a closing dressing bolster for placing on the patient's epidermis over the linear wound, a sealing subsystem for providing a seal over the closing dressing bolster and the patient, and a reduced-pressure subsystem for delivering reduced pressure to the sealing subsystem. The sealing subsystem and reduced pressure subsystem are operable to deliver reduced pressure to the closing dressing bolster. The closing dressing bolster is operable under reduced pressure to develop a inward closing. The closing dressing bolster may include one or more closing members on each side of a center wound area to create the inward closing when under reduced pressure. A compressive force may also be developed. Other systems and methods are presented.

Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Abstract: A system for providing reduced-pressure treatment to a moveable tissue site, such as a joint, includes a flexible dressing bolster. The flexible dressing bolster has a first side and a second, inward-facing side, and a plurality of flexion joints formed on the flexible dressing bolster. The system further includes a sealing subsystem for providing a fluid seal over the flexible dressing bolster and the patient's epidermis and a reduced-pressure subsystem for delivering a reduced pressure to the sealing subsystem. The sealing subsystem and reduced-pressure subsystem are operable to deliver a reduced pressure to the moveable tissue site. The flexible dressing bolster is operable to allow articulation or movement of the moveable tissue site. The sealing subsystem may include a drape with folds. Other systems, apparatuses, and methods are presented.

Abstract: A patch package structure which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, a peripheral area of the first sheet material having been sealed to a peripheral area of the second sheet material to constitute the package, and a patch disposed in the package; in which the patch includes a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner which protects the pressure-sensitive adhesive surface of the pressure-sensitive adhesive layer, the release liner having a weakening line for assisting a removal of the release liner; and in which the second sheet material has specific first protrudent part, second protrudent part, third protrudent part and elevated part in a central area thereof except the peripheral area thereof.

Abstract: A medical device for example a wound dressing having antibacterial and optionally, antifungal properties, are provided together with methods for making the device. An exemplary dressing includes a layer of silver-containing fabric, (optionally) a layer of absorbent material, and (optionally) a layer of flexible air-permeable and/or water-impermeable material. The dressing can be used for prophylactic and therapeutic care and treatment of skin infections and surface wounds (including surgical incisions), as a packing material, and as a swab for surface cleaning.

Abstract: A transdermal permeant delivery system for delivery of at least one permeant composition into a tissue membrane of a subject including a disposable substrate having at least a portion of a bottom surface of a first release liner connected to an upper surface of the substrate and a patch having a backing layer and a reservoir that is selectively removable from the top surface of the first release liner. In a connected position, a first portion of the backing layer of the patch is releaseably mounted to a top surface of the first release liner in spaced registration with a poration area of the substrate.

Abstract: The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.

Abstract: An adhesive plaster (10; 110; 600; 800) provided with one or more rupturable capsules (18; 118; 618; 818) containing one or more kinds of medication.

Abstract: Methods accelerate healing of a wound by applying a multilayer bandage to the wound. The multilayer bandage has a spun-bonded webbing comprising at least one partially or completely hydrolytically condensed silicon compound and a water-impervious or semi-permeable first membrane having at least one water-insoluble polymer. The webbing has a biologically degradable or biologically resorbable structure and is brought into direct contact with the wound by placing the webbing in or on the wound.

Abstract: The invention relates to a therapeutic system, designed as a laminate and comprising at least one adhesive laminate layer, and to a therapeutic device having such a therapeutic system. For this purpose, at least one laminate layer or one intermediate layer and/or one intermediate layer arranged between two laminate layers contains superparamagnetic nanoparticles. The therapeutic device having said therapeutic system comprises at least one electrically controllable system which is detachably connected to the therapeutic system. The electrically controllable system has a frequency-dependent electric resistance. During operation of the therapeutic device, the electrically controllable system generates an electric or magnetic field, which can be varied in orientation and intensity over time and penetrates the superparamagnetic nanoparticles.

Abstract: An adherent article with a first substrate, soluble or dispersible in aqueous solutions, with a first and second side, and an aqueous-insoluble second substrate disposed on at least a portion of the second side of the first substrate, optionally, with an adhesive applied to at least a portion of the first side of the first substrate, and a release liner positioned over a portion of the first substrate or adhesive to cover and protect at least a portion of the adhesive.

Abstract: A medicated, transdermal foot patch includes a cushioning layer, and an adhesive layer comprised of an adhesive material that adheres the patch to the skin of the foot when the patch is applied to the foot with the adhesive layer in direct contact with the skin. A removable liner is placed over the adhesive layer to protect the adhesive layer until the adhesive layer is ready to be applied directly to the skin. One or more pain-relieving compounds is deliverable to the skin when the patch is applied to the foot with the adhesive layer is in direct contact with the skin.

Abstract: A diffusing device for treating tissue has multiple cells arranged in a cell layer, the cells filled with or charged with a therapeutic agent, an occlusive layer in direct communication with the cell layer, and a diffusion layer in direct communication with the cell layer. In use the diffusing device is sealed peripherally about an area of tissue and therapeutic agent is released from the cells through the diffusion layer based on the diffusion properties of the diffusion layer.

Abstract: A release agent applicator applies release agent to an imaging drum and absorbs release agent metered from the drum to extend the operational life of an image drum maintenance unit. The applicator includes a reservoir for storing release agent, the reservoir having a plurality of perforations for enabling release agent to seep from the reservoir, a containment membrane for wicking release agent from the perforations of the reservoir, and a delivery layer for delivering release agent from the containment membrane to an imaging drum, the delivery layer having pores in a range of about 50 ?m to about 200 ?m.

Abstract: The present invention relates to a moist, layered bioadhesive patch comprising one or more polymers. Moreover, the invention relates to a method of producing a monolayered film and a method of drying said film. Additionally, the invention relates to methods of producing bioadhesive, layered patches by combining layers of the monolayered film to obtain a desired thickness of the patch. Patches according to the invention may be used as such, or for delivering pharmaceutically active compounds, such as in a drug delivery system.

Abstract: A reduced pressure treatment system is provided for delivering a reduced pressure to a tissue site comprising a distribution manifold including a backing substrate with a first side and a second side and a plurality of protrusions positioned on the first side of the backing substrate, each of the protrusions having a substantially circular cross-sectional shape and having a diameter of between about 0.1 and 2.0 millimeters, the backing substrate having a plurality of apertures formed therein to allow fluid communication between the first side and the second side opposite the first side. A reduced pressure source fluidly connects to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to the tissue.

Abstract: Methods and devices transmit micromechanical forces locally on the millimeter to micron scale for promoting wound healing. Micromechanical forces can selectively be applied directly to tissue, in some embodiments, by using microchambers fluidically connected to microchannels. Each chamber, or in some cases, group of chambers, may be associated with a valve to control vacuum pressure, positive pressure, liquid delivery, and/or liquid removal from each chamber or group of chambers. Application of embodiments of the invention may shorten wound-healing time, reduce costs of therapy, enable restoration of functional tissue, and reduce the need for more invasive therapies, including surgery.

Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.

Abstract: A blood leakage detection device for attachment to the skin of a patient at a wound such as one caused by insertion a cannula into a vein or artery comprises a support of a flexible material having a top side and an opposite bottom side, a zone of adhesive for attachment to the skin on the bottom side of the support extending along its periphery except for a sector of from about 5° to about 150°, a blood absorbent patch disposed on the support and extending inwardly of the adhesive zone and, optionally, in the sector, and a blood detection probe comprising a probe head disposed at or near the center of the support in the absorbent patch or abutting the bottom side thereof. A blood transport element can be disposed between the support and the absorbent patch.

Abstract: Described herein are abuse-resistant multi-layer transdermal patches comprising opioids and opioid prodrugs having a barrier layer located between the layer containing opioid or opioid prodrug and a layer containing an opioid antagonist or opioid antagonist prodrug.